EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

Yan-Song Lin, Shuo Li, Xia Yang, Rong-Ping Guo, Yu-Hua Huang, Kun-Hao Bai, Jun Weng, Jing-Ping Yun

Journal of Cancer Research and Clinical Oncology · 18.06.2024 · 150 (6)

DOI: 10.1007/s00432-024-05795-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 18.06.2024. Verfasst von Yan-Song Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Quinolines, Phenylurea Compounds, Bile Duct Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Limited treatment options exist for unresectable intrahepatic cholangiocarcinoma (ICC), with systemic chemotherapy (SC) serving as the primary approach. This study aimed to assess the effectiveness of first-line hepatic arterial infusion chemotherapy (HAIC) in combination with lenvatinib and PD-(L)1 inhibitors (HLP) compared to SC combined with PD-(L)1 inhibitors (SCP) or SC alone in treating unresectable ICC.

Methods

Patient with unresectable ICC who underwent first-line treatment with HLP, SCP or SC from January 2016 to December 2022 were retrospectively analyzed. The study evaluated and compared efficacy and safety outcomes across the three treatment groups.

Results

The study comprised 42, 49, and 50 patients in the HLP, SCP, and SC groups, respectively. Median progression-free survival (PFS) times were 30.0, 10.2, and 6.5 months for HLP, SCP, and SC groups. While the SC group had a median overall survival (OS) time of 21.8 months, the HLP and SCP groups hadn’t reached median OS. The HLP group demonstrated significantly superior PFS ( p < 0.001) and OS ( p = 0.014) compared to the others. Moreover, the HLP group exhibited the highest objective response rate (ORR) at 50.0% and the highest disease control rate (DCR) at 88.1%, surpassing the SC group (ORR, 6.0%; DCR, 52.0%) and SCP group (ORR, 18.4%; DCR, 73.5%) ( p < 0.05). Generally, the HLP group reported fewer grades 3–4 adverse events (AEs) compared with others.

Conclusion

In contrast to systemic chemotherapy with or without PD-(L)1 inhibitors, the triple combination therapy incorporating HAIC, lenvatinib, and PD-(L)1 inhibitors showcased favorable survival benefits and manageable adverse events for unresectable ICC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaQuinolinesPhenylurea CompoundsBile Duct NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions, Intra-ArterialHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultImmune Checkpoint InhibitorsB7-H1 AntigenAged, 80 and overHepatic Artery

Stichwörter der Autor:innen

Hepatic arterial infusion chemotherapyLenvatinibPD-(L)1 inhibitorsSystemic chemotherapyUnresectable intrahepatic cholangiocarcinoma

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsImmune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
  • Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
  • Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
  • Department of Endoscopy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. yunjp@sysucc.org.cn.
  • Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. yunjp@sysucc.org.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lin, Y. S., Li, S., Yang, X., Guo, R. P., Huang, Y. H., Bai, K. H., Weng, J., & Yun, J. P. (2024). First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology, 150(6). https://doi.org/10.1007/s00432-024-05795-2

Vancouver

Lin YS, Li S, Yang X, Guo RP, Huang YH, Bai KH, et al. First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology. 2024;150(6). doi:10.1007/s00432-024-05795-2

BibTeX
@article{Lin2024,
  author = {Lin, Yan-Song and Li, Shuo and Yang, Xia and Guo, Rong-Ping and Huang, Yu-Hua and Bai, Kun-Hao and Weng, Jun and Yun, Jing-Ping},
  title = {First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {6},
  doi = {10.1007/s00432-024-05795-2}
}
Kostenlos starten →